Effect of Bacillius Coagulans and Galactomannans on Obese Patients Undergoing Sleeve Gastrectomy, A Randomized-Controlled Clinical Trial

• Published in: Alternative therapies in health and medicine Vol. 27; pp. 138 - 145
• Main Authors: Kazzi, Fay, Daher, Noha, Zimmerman, Grenith, Garcia, Manuel, Schmidt, Nicholas, Scharf, Keith
• Format: Journal Article
• Language: English
• Published: United States InnoVision Health Media, Inc 01.06.2021
• Subjects: Blood pressure; Clinical trials; Gastrointestinal surgery; Medical records; Obesity; Prebiotics; Probiotics; Surgical outcomes; Vitamin deficiency; Weight control
• ISSN: 1078-6791

The purpose of this study was to examine the effect of probiotics and prebiotics (LactoWise®) on weight loss, blood pressure, and clinical lab values in morbidly obese patients undergoing laparoscopic sleeve gastrectomy (LSG). Materials Methods: Sixty patients undergoing LSG were recruited to participate in the study and randomized into either a LactoWise® or placebo group. The LactoWise® group (LWG) received 4.5 billion live cells of bacillus coagulans and galactomannans (300 mg); the placebo group received 600 mg of calcium citrate yielding 126 mg of elemental calcium. Both groups took their assigned capsule daily for 3-months post-surgery. Standard clinical lab values were measured pre-surgery and at 3-months post-surgery. Weight and blood pressures were measured at baseline, 2 weeks, 6 weeks, and 3 months post-surgery. A total of 35 patients with a mean age of 47.7±12.4 years and a mean body mass index (BMI) of 46.6±8.2 kg/m2 completed the study. There was a significant difference in BMI at baseline between the two study groups (43.0±7.0 vs. 49.2±8.3, p=0.02). Weight loss was greater in the LWG compared to placebo at 6 weeks but showed no significant difference at 3 months post-op. In addition, there was a significant drop in triglycerides (TG) (p=0.02) over time in the LWG (p=0.01). The LWG had a significant decrease in AST and LDL compared to the placebo group (p=0.03). Bariatric surgery (BS) produces positively impacting metabolic results in morbidly obese patients. Our study shows that in the case of triglycerides, LDL, weight loss and AST, administering of a probiotic/prebiotic blend may play a role in improving clinical outcomes of morbidly obese patients undergoing LSG.